Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 3:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: IDH1 Gene Mutation Clear all
Completed Phase 1Phase 2 Interventional Results available

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

NCT02719574
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
FT-2102 (olutasidenib), Azacitidine, Cytarabine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
19
States / cities
Los Angeles, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Jun 25, 2026, 3:54 PM EDT
Active, not recruiting Early Phase 1 Interventional

Niraparib In Recurrent IDH 1/2 Gliomas

NCT05406700
View directory record Official record
Conditions
Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation, Glioma, Malignant
Interventions
Niraparib, Resection/Treatment with Niraparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 25, 2026, 3:54 PM EDT
Recruiting Phase 2 Interventional

Study of Olutasidenib and Temozolomide in HGG

NCT06161974
View directory record Official record
Conditions
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Interventions
Olutasidenib + TMZ
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
12 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 3:54 PM EDT
Active, not recruiting Phase 2 Interventional

AG-120 in People With IDH1 Mutant Chondrosarcoma

NCT04278781
View directory record Official record
Conditions
Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, IDH1 Gene Mutation
Interventions
AG-120
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 25, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

NCT02492737
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
Interventions
AG881
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Jun 25, 2026, 3:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

NCT05588141
View directory record Official record
Conditions
Brain Tumor, Cancer
Interventions
Zotiraciclib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 25, 2026, 3:54 PM EDT
Recruiting Phase 1 Interventional

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

NCT06543381
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Olutasidenib
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Duarte, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 25, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

NCT03564821
View directory record Official record
Conditions
IDH1 Mutation Myeloid Neoplasms
Interventions
Ivosidenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 25, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

NCT03127735
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
BAY1436032
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Buffalo, New York • New York, New York • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Jun 25, 2026, 3:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

NCT02704858
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Perillyl alcohol
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jun 25, 2026, 3:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT06501625
View directory record Official record
Conditions
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Interventions
Ivosidenib, Durvalumab (for the first 8, 21-day, cycles), Gemcitabine (for the first 8, 21-day, cycles), Cisplatin (for the first 8, 21-day, cycles), Durvalumab (starting from cycle 9), Ivosidenib Recommended Combination Dose (RCD)
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Los Alamitos, California • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 25, 2026, 3:54 PM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

NCT03303950
View directory record Official record
Conditions
Anemia, ASXL1 Gene Mutation, EZH2 Gene Mutation, IDH1 Gene Mutation, IDH2 Gene Mutation, Plasma Cell Myeloma, Primary Myelofibrosis, Recurrent Plasma Cell Myeloma, Secondary Myelofibrosis, Thrombocytopenia
Interventions
Busulfan, Cyclophosphamide, Fludarabine, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jun 25, 2026, 3:54 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

NCT06291987
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
Ivosidenib, Ruxolitinib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jun 25, 2026, 3:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

NCT05921760
View directory record Official record
Conditions
IDH1-mutant Cholangiocarcinoma
Interventions
Ivosidenib, Nivolumab, Ipilimumab
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 25, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

NCT02481154
View directory record Official record
Conditions
Glioma
Interventions
AG881
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jun 25, 2026, 3:54 PM EDT
Recruiting Phase 2 Interventional

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

NCT06782542
View directory record Official record
Conditions
Acute Myeloid Leukemia, IDH1 Mutation
Interventions
Olutasidenib, Venetoclax, Azacitidine
Drug
Lead sponsor
Justin Watts, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 25, 2026, 3:54 PM EDT